November 2, 2015
Eisai CEO Haruo Naito Eisai managed to secure a revenue increase of 2.4% in April-September as sales of four global products including Halaven (eribulin) and Lenvima (lenvatinib) expanded in Asia, Europe, and the Middle East. In the first half of...read more